BioSpace News Archive

Business

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Intensity Therapeutics, Inc. (“Intensity” or “the Company”) (Nasdaq: INTS) announces first quarter 2024 financial results and provides a corporate update.

May 9, 2024
·
9 min read
Drug Development

Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) today announced that the first patient has been dosed in the Phase 2 portion of the AlphaBreak trial evaluating FPI-2265 (225Ac-PSMA I&T) in patients with metastatic castration-resistant prostate cancer (mCRPC).

May 9, 2024
·
6 min read
Business

Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

Guardant Health, Inc., a leading precision oncology company, reported financial results for the quarter ended March 31, 2024.

May 9, 2024
·
16 min read
Business

NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three months ended March 31, 2024 and provides a business update.

May 9, 2024
·
10 min read
Business

Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates

Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2024 and provided general business updates.

May 9, 2024
·
8 min read
Bio NC

IQVIA CFO Ron Bruehlman to Speak at the Bank of America Health Care Conference on May 14, 2024

IQVIA Holdings Inc. announced that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Bank of America Health Care Conference in Las Vegas on Tuesday, May 14, 2024 at 12:20 p.m. ET.

May 9, 2024
·
1 min read
Business

Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

May 9, 2024
·
13 min read
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia

Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced the commercial launch of DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia, providing patients and physicians with a compelling new treatment option for a painful and disabling chronic condition.

May 9, 2024
·
11 min read
Business

Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended March 31, 2024.

May 9, 2024
·
13 min read
Verisense Health Elects Josh Tolkoff to its Board of Directors

Josh brings extensive medical device, investment, and growth management experience to his new role.

May 9, 2024
·
2 min read